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Myths are common in science.1 Once assimilated into popular belief or medicine, they can 
be difficult to dispel, with consequences that may not be trivial. They have the potential to 
hold back some avenues of science,1 inhibit publication of studies that refute ‘what is 
already known,’ and misdirect research or healthcare dollars.  
Here, we refer to an interesting Article published in the NEJM, 20022, reviewing “The effect 
of infections on susceptibility to autoimmune and allergic diseases.” The article was 
intended to be hypothesis generating and has attracted over 2000 citations (Google Scholar 
9-May-2017). However, specific aspects which were likely intended as interesting, thought-
provoking ideas, are now commonly misrepresented as fact or common knowledge. We 
draw particular attention to Figure 1 of the review article which reports an “Inverse 
relationship between the incidence of prototypical infectious diseases and the incidence of 
immune disorders” in two separate panels.2 We do not intend to critique (or have issue 
with) other aspects of this interesting and influential review article. However, Figure 1 
deserves  further consideration as, even today, it regularly features as an established fact in 
keynote presentations at global venues by influential and well intending thought leaders 
based at leading research institutes (for examples, see3,4). Whilst there may (or may not) be 
a relationship between infections and autoimmune/allergic diseases, what is presented in 
Figure 1 is the focus of this Viewpoint given the persuasiveness of the conclusions drawn. 
The author applied ecological methodology to depict temporal changes in the incidence of 
different diseases and thus draw conclusions about links between them. For such 
comparisons to be valid there are a number of key requirements, including suitability of the 
data presented for the purpose of addressing the issue at hand. The two panels of Figure 1 
are compared to make the hypothesised link between infections and autoimmune/allergic 
disease: Panel A shows decreasing “incidence” of infectious diseases, mainly in the USA; 
Panel B shows autoimmune and allergic diseases, all in non-USA countries. While the former 
are largely from population databases, the latter are based on findings from disparate single 
studies in different populations. Data on type 1 diabetes are from Finland,5 even though 
USA data were available over the graphed period.6 Further, the Finnish data relates only to 
children under 15 years of age, and as the original authors pointed out, the small sample 
size may give unreliable incidence estimates.5 At the same time, there was no increase in 
incidence of type 1 diabetes in a nearby country, Norway.7 The small sample size problem 
occurs again with the incidence estimates provided for multiple sclerosis. Here the data are 
from the small population in the northern part of Sardinia.8 The data on asthma are from 
young male conscripts in Belgium – which makes them a rather different population and 
challenging to compare with the USA data on infectious diseases. 
Other elements of Figure 1 create further challenges when drawing conclusions. The y-axes 
report incidence (%) of disease, with scales from 0-100 for infectious diseases, and 100 to 
400 for autoimmune and allergic diseases. Although limited space may have prevented a 
detailed explanation, it appears likely this is not disease incidence, but the percentage 
change in incidence from the oldest data point. Further, for several of the cited studies 
incidence was not measured – the hepatitis A data are not incidence but seroprevalence;9 
the asthma data are prevalence and it is not clear whether the plotted data are based on 
the prevalence of self-reported asthma or the proportion with airway hyper-
responsiveness.10  
Another challenge is locating the original data presented in the Figure from the cited papers. 
For example, the figure shows a steep increase in the incidence of multiple sclerosis (MS), 
beginning in 1950 – and this figure provides the baseline (comparator) incidence. However 
the cited study, from which the data are derived,8 reports findings only from 1968 onwards. 
A similar problem occurs with the data for hepatitis A, with Figure 1 showing “Incidence” 
data starting at around 1970, yet in the cited paper, data are available only from 1985.9  For 
Crohn’s disease, we are less clear which data from the cited review are used (noting that the 
authors listed under ‘references’ did not correspond to what we were able to find11), or 
whether the line in Figure 1 represents some combination of data from disparate 
populations. Incidence of tuberculosis has been falling in the USA over the time period 
shown, but, as data from the World Bank12 show, almost any incidence pattern is available, 
according to the country selected. 
The NEJM 2002 article presents an interesting and compelling story,2 including a broader 
discussion of plausible underlying mechanisms and immune-mediated pathways providing 
support for Strachan’s hygiene hypothesis.13 Comparisons of temporal patterns in 
population incidence of disease are, by necessity, of an ecological design. A valid 
comparison, however, requires that the changes are occurring in the same populations, at 
the same time. Confining comparisons to incidence rather than prevalence ensures a 
comparison of disease patterns that are not confounded by changes in care and/or 
treatment. Nevertheless, Figure 1 has become pervasive, cited and presented many times as 
a stand-alone-graphic in isolation of the wider original article,2 and the concepts depicted 
seemingly accepted as common knowledge. The consequences may be significant. For 
example, we do not know what the incidence of MS is across the USA (the last study was 
conducted in 1975; source: US National MS Society).  We assume it is increasing, as Figure 1 
depicts. We seek environmental risk factors for MS that are driving this rapid increase, too 
rapid to be the result of genetic factors. Yet, researchers and funding bodies may not 
recognize that we do not have the evidence to support a general assumption of increasing 
incidence of MS  – avoiding applications that seek to clarify the temporal patterns, and/or 
supporting funding that relies on the underlying assumption. We do not seek to review the 
worldwide evidence on MS incidence here – suffice to say that it appears to be increasing in 
some locations, and stable or even decreasing in others.14-18  
We need the best possible evidence to drive our understanding of disease risk factors. We 
encourage the scientific community to challenge assumptions based on apparent evidence, 
critically evaluating the underlying data. It is easy to be misled, and to travel down fruitless 
pathways that take time and funds, trying to solve the origins of temporal and geographic 
patterns that may or may not exist.  
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